Decoy Therapeutics Inc.
$5.89
▼
-7.5%
2026-04-21 06:23:00
decoytx.com
NCM: DCOY
Explore Decoy Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.09 M
Current Price
$5.89
52W High / Low
$415.8 / $5.4
Stock P/E
—
Book Value
$11.07
Dividend Yield
—
ROCE
-379.33%
ROE
-3.38%
Face Value
—
EPS
$-129.1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
11
Beta
0.36
Debt / Equity
0.15
Current Ratio
2.13
Quick Ratio
2.13
Forward P/E
-0.3
Price / Sales
—
Enterprise Value
$-7.6 M
EV / EBITDA
1.86
EV / Revenue
—
Rating
None
Target Price
$30
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 2. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 3. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 4. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 5. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 6. | NextCure, Inc. | $11.7 | — | $41.66 M | — | -145.43% | -1.11% | $15.74 / $3.85 | $9.97 |
| 7. | Verastem, Inc. | $6.52 | — | $557.75 M | — | -97.68% | -14.8% | $11.24 / $4.01 | $0.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.03 M | -0.9 M | -0.97 M | -1.72 M | -1.49 M | — |
| Net Profit | -8.98 M | -0.87 M | -0.96 M | -1.71 M | -1.46 M | — |
| EPS in Rs | -16.88 | -1.64 | -1.8 | -3.21 | -2.75 | -136.56 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -12.61 M | -5.73 M | -12.89 M | -22.98 M |
| Net Profit | -12.52 M | -5.58 M | -12.54 M | -31.61 M |
| EPS in Rs | -23.53 | -10.48 | -23.58 | -59.42 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.06 M | 3.02 M | 6.59 M | 14.65 M |
| Total Liabilities | 5.17 M | 1.51 M | 1.3 M | 4.27 M |
| Equity | 5.89 M | 1.51 M | 5.29 M | 10.38 M |
| Current Assets | 10.99 M | 2.99 M | 6.52 M | 14.52 M |
| Current Liabilities | 5.17 M | 1.51 M | 1.3 M | 4.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.83 M | -4.53 M | -12.85 M | -17.6 M |
| Investing CF | 0.76 M | 0 M | 0 M | -1.5 M |
| Financing CF | 12.34 M | 1.06 M | 6.64 M | 1.99 M |
| Free CF | -5.4 M | -4.53 M | -12.85 M | -19.1 M |
| Capex | -0.58 M | — | — | -1.5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 55.55% | 60.32% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-09 | 1:0.0833333 |
| 2025-08-18 | 1:0.0666667 |
| 2024-06-17 | 1:0.125 |
| 2022-10-17 | 1:0.04 |